In a NAFLD mouse model and a PA-induced HepG2 cell model, liraglutide has been observed to alleviate hepatic steatosis by modulating the expression of autophagy substrates LC3-II and SQSTM1/P62, thereby activating the autophagy-lysosomal pathway (ALP) regulated through the TFEB pathway (183). Here, TFEB is linked to metabolic dysfunction-associated steatotic liver disease.